.Attribute Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin led to strengthened progression-free and overall survival, triggering FDA approval as well as a brand-new therapy choice for individuals.